This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

Since he was arrested, Luigi Mangione has gained support from the public. Mangione is currently in custody in a Pennsylvania state prison. 1 He has been charged with first-degree murder in ...

Disease-free and overall survival outcomes were similar across dosing schedules. Patients with high-risk early breast cancer have similar survival outcomes with different dosing schedules of ...

Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

In the Mithic-FL1 trial, patients with newly diagnosed high-burden follicular lymphoma (FL) demonstrated complete response (CR) rates of 80% and manageable adverse events with outpatient ...